Indeed, SphK1 inhibition by the immunomodulator FTY720, which is also a functional antagonist of S1P receptors, downregulated the PI3K/AKT/mTOR signaling pathways and EGFR expression in SK-Mel-28 and A375 human melanoma cells, resulting in an increased sensitivity to cisplatin [113]. This evidence concerns the gene SPHK1 and melanoma.